Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

4.11USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
63,582
52-wk High
$9.31
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Pain therapeutics reports Q3 loss per share $0.40
Wednesday, 1 Nov 2017 08:00am EDT 

Nov 1 (Reuters) - Pain Therapeutics Inc :Pain therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.40.Pain Therapeutics Inc - ‍still expects net cash usage in calendar year 2017 may be approximately $10 million​.Pain Therapeutics - ‍following resubmission of Remoxy NDA in Q1 2018, Co believes net cash usage in 2018 will decrease significantly compared to 2017.  Full Article

Pain Therapeutics announces upcoming meeting with FDA
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces upcoming meeting with FDA.Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​.Pain Therapeutics Inc - ‍meeting is planned for November 14, 2017 at FDA headquarters​.Pain Therapeutics Inc - ‍remoxy NDA remains on-track for a planned resubmission in Q1 2018​.  Full Article

Pain Therapeutics reports Q2 loss per share $0.64
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update.Q2 loss per share $0.64.  Full Article

Pain Therapeutics announces FDA clears investigational new drug application for PTI-125
Monday, 31 Jul 2017 08:00am EDT 

July 31 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125.Pain Therapeutics Inc - ‍company's phase I study with PTI-125 will be funded by a $1.7 million grant from NIH​.Pain Therapeutics Inc - ‍FDA cleared its investigational new drug (IND) application for PTI-125, a novel drug candidate to treat Alzheimer's disease​.Pain Therapeutics- ‍clinical testing with PTI-125 will begin shortly, with funding provided by a $1.7 million research grant from National Institutes of Health​.  Full Article

Pain Therapeutics announces reverse stock split
Monday, 8 May 2017 09:14am EDT 

May 8 (Reuters) - Pain Therapeutics Inc :Pain therapeutics announces reverse stock split.Pain therapeutics inc - that it will effect a 7-for-1 reverse split of its outstanding shares of common stock effective may 9, 2017.  Full Article

Pain Therapeutics reports Q1 loss per share $0.06
Tuesday, 25 Apr 2017 05:47pm EDT 

April 25 (Reuters) - Pain Therapeutics Inc -:Pain Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.06.  Full Article

Pain Therapeutics files for mixed shelf of up to $75 mln
Friday, 14 Apr 2017 06:25pm EDT 

Pain Therapeutics Inc :Files for mixed shelf of up to $75 million - sec filing.  Full Article

Pain Therapeutics announces resignation of Peter Roddy as CFO
Friday, 17 Feb 2017 09:02am EST 

Pain Therapeutics Inc :On Feb 14, 2017, Peter Roddy resigned, effective March 9, 2017, as vice president, chief financial officer.  Full Article

Pain Therapeutics reports qtrly loss per share $0.06
Friday, 17 Feb 2017 09:00am EST 

Pain Therapeutics Inc : Pain therapeutics reports 2016 financial results . Qtrly loss per share $0.06 .Pain Therapeutics - in first two quarters of 2017, company expects its quarterly net cash burn rate will range from $2.0 million to $2.5 million.  Full Article

Pain Therapeutics to discuss remoxy ER with FDA
Tuesday, 20 Dec 2016 09:00am EST 

Pain Therapeutics Inc: Pain therapeutics to discuss remoxy® ER with FDA . Plans to meet with FDA in person on Monday, February 13, 2017 to discuss regulatory path forward for remoxy ER . Pain therapeutics - during its upcoming meeting with FDA, company plans to open a scientific dialogue around intranasal (snorting) route of abuse . Company will provide details of this FDA meeting after receipt of final meeting minute .Pain therapeutics - company believes remoxy ER's thick, sticky, high-viscosity drug mass is a key feature of its abuse deterrent properties.  Full Article

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results